이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Medical Developments International 과거 수익 실적

과거 기준 확인 0/6

Medical Developments International의 수입은 연평균 -47.3%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 35.6%의 비율로 증가했습니다. 매출은 연평균 9%의 비율로 증가해 왔습니다.

주요 정보

-47.3%

수익 성장률

-44.2%

EPS 성장률

Pharmaceuticals 산업 성장	31.2%
매출 성장률	9.0%
자기자본 수익률	-25.4%
순이익	-57.3%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Medical Developments International 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

CHIA:MVP 수익, 비용 및 수입 (AUD Millions )
날짜	수익	수익	G+A 비용
31 Dec 23	34	-19	43
30 Sep 23	33	-12	39
30 Jun 23	32	-6	36
31 Mar 23	29	-4	32
31 Dec 22	26	-2	28
30 Sep 22	24	-7	26
30 Jun 22	22	-12	25
31 Mar 22	22	-16	26
31 Dec 21	22	-19	27
30 Sep 21	24	-16	24
30 Jun 21	25	-13	20
31 Mar 21	25	-7	16
31 Dec 20	24	-1	11
30 Sep 20	23	0	11
30 Jun 20	23	0	11
31 Mar 20	22	1	10
31 Dec 19	22	1	10
30 Sep 19	22	1	10
30 Jun 19	21	1	10
31 Mar 19	20	1	10
31 Dec 18	19	0	10
30 Sep 18	18	0	10
30 Jun 18	17	0	9
31 Mar 18	18	1	9
31 Dec 17	18	2	8
30 Sep 17	18	2	8
30 Jun 17	18	2	8
31 Mar 17	18	2	8
31 Dec 16	18	2	7
30 Sep 16	17	2	7
30 Jun 16	15	2	7
31 Mar 16	14	1	6
31 Dec 15	12	1	5
30 Sep 15	12	1	5
30 Jun 15	12	2	4
31 Mar 15	11	1	4
31 Dec 14	10	1	4
30 Sep 14	10	1	4
30 Jun 14	9	1	4
31 Mar 14	10	1	4
31 Dec 13	10	1	4
30 Sep 13	11	2	4
30 Jun 13	12	2	4

양질의 수익: MVP 은(는) 현재 수익성이 없습니다.

이익 마진 증가: MVP 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: MVP 은(는) 수익성이 없으며 지난 5년 동안 연간 47.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 MVP 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: MVP 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 28.2% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: MVP 현재 수익성이 없기 때문에 마이너스 자본 수익률( -25.38% )을 갖습니다.

Medical Developments International 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024

Full year 2023 earnings released: AU$0.067 loss per share (vs AU$0.17 loss in FY 2022)

Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

First half 2023 earnings released: EPS: AU$0.032 (vs AU$0.10 loss in 1H 2022)

Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023

Full year 2022 earnings released: AU$0.17 loss per share (vs AU$0.18 loss in FY 2021)

Recent updates

New minor risk - Profitability

Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024

Medical Developments International Limited, Annual General Meeting, Oct 27, 2023

Full year 2023 earnings released: AU$0.067 loss per share (vs AU$0.17 loss in FY 2022)

Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023

Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

New minor risk - Share price stability

First half 2023 earnings released: EPS: AU$0.032 (vs AU$0.10 loss in 1H 2022)

Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023

Medical Developments International Limited Discontinues China Clinical Trials

No independent directors

Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022

Medical Developments International Limited, Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: AU$0.17 loss per share (vs AU$0.18 loss in FY 2021)

Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023

Medical Developments International Limited to Report Fiscal Year 2022 Results on Aug 26, 2022

Medical Developments International Limited Appoints Tara Eaton as General Counsel and Company Secretary, Effective August 8, 2022

No independent directors

Medical Developments International Limited Announces That US Food and Drug Administration Lifts Clinical Hold on Penthrox

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medical Developments International Limited to Report Q2, 2022 Results on Feb 24, 2022

Non-Executive Chairman recently bought AU$306k worth of stock

Non-Executive Chairman recently bought AU$1.0m worth of stock

Full year 2021 earnings released: AU$0.18 loss per share (vs AU$0.006 profit in FY 2020)

Medical Developments International Limited Provides Sales Guidance for the Fiscal Year 2022

Medical Developments International Limited Announces Earnings Guidance for the Year Ended June 30, 2021

Non-Executive Chairman recently bought AU$534k worth of stock

Medical Developments International Limited Appoints Mary Sontrop as Non-Executive Director

Revenue misses expectations

First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.004 profit in 1H 2020)

New 90-day low: AU$6.05

New 90-day high: AU$7.13

Medical Developments International Limited Announces Executive Changes

New 90-day high: AU$6.59

Medical Developments International Limited Appoints Brent Macgregor as Chief Executive Officer, Effective November 1, 2020

Medical Developments International Limited Declares No Dividend for the Full Year Ended 30 June 2020

New 90-day low: AU$5.27

New 90-day low - AU$5.51

Full year earnings released

Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX Emerging Companies Index

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기